An image is an estimate under constraints
The body does not emit a ready-made picture. A scanner perturbs tissue, records a noisy response, and reconstructs an estimate that must be good enough for one decision.
Create contrast
An image starts with a physical difference between tissues: attenuation, acoustic impedance, proton relaxation, or tracer uptake. If disease does not change the chosen signal, processing cannot reveal it.
- Measure
- Contrast-to-noise, tissue specificity
- Failure boundary
- Weak or non-specific biological contrast
What the record shows at this step
- Reported evidence
- Iodine and gadolinium agents, and targeted radiotracers, exist precisely because native contrast is often insufficient for the clinical question.
- Where it is moving
- Spectral and photon-counting acquisition separates materials by energy, and molecular tracers extend contrast to receptor and metabolic states.
- Principal risk
- Weak or non-specific biological contrast
Evidence statements describe cleared systems or published studies. “Where it is moving” is an editorial reading of the direction, not an announced capability.
Deliver energy or tracer
X-rays, sound, radiofrequency pulses, magnetic gradients, or radiotracers probe the body. More signal can improve certainty, but may add dose, heating, time, or biological burden.
- Measure
- Dose, field strength, acoustic output
- Failure boundary
- Radiation, heating, contrast, and tracer exposure
What the record shows at this step
- Reported evidence
- The FDA publishes a broad typical effective-dose range of roughly 1 to 10 mSv for diagnostic CT, with wide variation by exam and protocol.
- Where it is moving
- Total-body PET converts a large sensitivity gain into either a much shorter scan or a substantially lower administered dose.
- Principal risk
- Radiation, heating, contrast, and tracer exposure
Evidence statements describe cleared systems or published studies. “Where it is moving” is an editorial reading of the direction, not an announced capability.
Detect the return
Detectors and coils turn small physical responses into electrical measurements. Higher efficiency can buy lower dose, shorter scans, or finer resolution.
- Measure
- Quantum efficiency, bandwidth, dynamic range
- Failure boundary
- Electronic noise, drift, saturation, and hardware cost
What the record shows at this step
- Reported evidence
- Digital radiography removed film entirely; the first photon-counting CT system was cleared in 2021 and records individual photons and their energy.
- Where it is moving
- Semiconductor-on-chip ultrasound transducers and denser PET crystal arrays move detector cost onto a semiconductor cost curve.
- Principal risk
- Electronic noise, drift, saturation, and hardware cost
Evidence statements describe cleared systems or published studies. “Where it is moving” is an editorial reading of the direction, not an announced capability.
Sample enough evidence
A system records one projection or many views through space and time. Motion and anatomy determine how much data is enough for the clinical question.
- Measure
- Coverage, temporal resolution, acquisition time
- Failure boundary
- Motion, incomplete angles, patient throughput
What the record shows at this step
- Reported evidence
- Undersampled MRI acquisition with constrained reconstruction is commercially deployed and shortens examinations at comparable reported quality.
- Where it is moving
- Acquisition that stops when the evidence is sufficient, rather than when a fixed protocol ends, is the open research direction.
- Principal risk
- Motion, incomplete angles, patient throughput
Evidence statements describe cleared systems or published studies. “Where it is moving” is an editorial reading of the direction, not an announced capability.
Reconstruct an estimate
Algorithms convert noisy, incomplete measurements into an image. Iterative and learned methods exchange computation and prior assumptions for time or dose.
- Measure
- Latency, artifact rate, uncertainty
- Failure boundary
- Suppressed pathology or invented structure
What the record shows at this step
- Reported evidence
- Learned reconstruction is cleared and in routine use on major CT and MRI platforms, where it substitutes computation for acquired signal.
- Where it is moving
- Calibrated uncertainty and failure detection, so a reconstruction can report when its prior is doing more work than the measurement.
- Principal risk
- Suppressed pathology or invented structure
Evidence statements describe cleared systems or published studies. “Where it is moving” is an editorial reading of the direction, not an announced capability.
Make a decision
Clinicians combine the image with history, priors, laboratory results, and consequences of error. The valuable output is a better decision, not a prettier picture.
- Measure
- Time to report, sensitivity, specificity
- Failure boundary
- Incidental findings, automation bias, limited workforce
What the record shows at this step
- Reported evidence
- A 2026 meta-analysis found moderate performance for portable low-field MRI in acute ischemic stroke and cautioned against using it alone to exclude disease.
- Where it is moving
- Evidence that faster or nearer imaging changes outcomes, rather than only changing where and how often images are made.
- Principal risk
- Incidental findings, automation bias, limited workforce
Evidence statements describe cleared systems or published studies. “Where it is moving” is an editorial reading of the direction, not an announced capability.
Resolution is not fidelity. Fidelity is preserving the evidence needed for the decision while exposing the uncertainty.
Five modalities, five kinds of truth
No scanner sees everything. Each modality makes a different tissue property visible and inherits a different physical limit.
| Modality | Primary contrast | Strongest use | Access advantage | Binding trade-off |
|---|---|---|---|---|
| X-ray | Differential attenuation | Bone, chest, lines and tubes | Very fast, mobile, inexpensive | Projection overlap, ionizing dose |
| Ultrasound | Reflected sound and Doppler shift | Motion, pregnancy, heart, vessels, procedures | Real time, handheld, no ionizing dose | Operator skill, bone and air block sound |
| CT | Many X-ray projections | Trauma, lung, vessels, acute abdomen | Fast 3D anatomy, broad availability | Dose, contrast, fixed infrastructure |
| MRI | Nuclear spin response | Brain, spine, joints, soft tissue, function | Many contrasts, no ionizing dose | Time, siting, safety, capital burden |
| PET | Radiotracer annihilation photons | Metabolism, receptors, treatment response | Molecular sensitivity | Tracer logistics, dose, coarse spatial detail |
Who is building what
Detector physics, reconstruction software, portability, and price are being pushed by different organisations with different claims. Search the record, or filter by the layer each programme is working on.
Siemens HealthineersNaeotom AlphaPhoton-counting detector CT
- Reported evidence
- Cleared by the FDA in 2021 as the first photon-counting clinical CT system; published studies report higher spatial resolution and intrinsic spectral data.
- Announced next step
- Wider deployment of photon-counting platforms across routine and lower-cost configurations.
- Unresolved risk
- Premium pricing, detector supply, and evidence that resolution and spectral data change management rather than only image appearance.
GE HealthCareRevolution / AIR Recon DLDeep-learning reconstruction across CT and MRI
- Reported evidence
- Cleared learned reconstruction is in routine use and is reported to shorten MRI acquisitions at comparable diagnostic quality.
- Announced next step
- Broader protocol coverage and shorter standard examinations.
- Unresolved risk
- Generalisation across scanners, body types, implants, and rare pathology; learned priors can suppress or invent structure.
PhilipsAmbition / Compressed SENSESealed low-helium magnets and undersampled acquisition
- Reported evidence
- Commercial systems reduce helium dependence and cut scan time through undersampling with constrained reconstruction.
- Announced next step
- Lower siting and service burden for conventional field strengths.
- Unresolved risk
- Capital cost remains high; siting and shielding still dominate the installed price.
HyperfineSwoopPortable ultra-low-field (0.064 T) brain MRI
- Reported evidence
- FDA-cleared portable system studied at the bedside; a 2026 meta-analysis found moderate performance in acute ischemic stroke.
- Announced next step
- Bedside neuroimaging in intensive care, emergency, and resource-limited settings.
- Unresolved risk
- Sensitivity is not equivalent to high-field MRI; the published caution is against using it alone to rule disease out.
Butterfly NetworkiQ3Semiconductor-on-chip whole-body probe
- Reported evidence
- A single probe covering multiple exam types at a probe-class price point, sold into point-of-care settings.
- Announced next step
- Guided acquisition that lowers the operator-skill barrier.
- Unresolved risk
- Operator dependence, scan quality assurance, documentation, and the risk of low-value imaging outside a referral pathway.
United ImaginguEXPLORERTotal-body PET with ~194 cm axial coverage
- Reported evidence
- Reported order-of-magnitude sensitivity gains, enabling much shorter scans or substantially reduced tracer dose.
- Announced next step
- Lower dose per study and higher patient throughput per scanner.
- Unresolved risk
- Very high capital cost and a small installed base; economics depend on utilisation and reimbursement.
Nano-X ImagingNanox.ARCCold-cathode source tomosynthesis
- Reported evidence
- A cleared system built around a different source technology, positioned on cost rather than capability.
- Announced next step
- Lower-cost distributed screening and musculoskeletal imaging.
- Unresolved risk
- Clinical adoption, throughput, service networks, and evidence of real diagnostic yield remain unsettled.
Refurbished equipment marketMulti-vendorCertified second-life CT, MRI, and PET/CT systems
- Reported evidence
- Documented purchase records show refurbished and entry systems well below premium list prices.
- Announced next step
- Extending equipment life and lowering the entry boundary for new sites.
- Unresolved risk
- Parts support, cybersecurity patching, and software licensing can end useful life before the hardware fails.
NIH / NIBIBPublic research programmesDetector physics, reconstruction, and access research
- Reported evidence
- Sustained public funding underlies detector, tracer, and reconstruction advances later commercialised.
- Announced next step
- Methods that lower dose, cost, or time without lowering diagnostic yield.
- Unresolved risk
- Laboratory performance does not establish clinical benefit; translation timelines are long.
FDA device programmesRegulatory pathwayClearance and post-market surveillance of imaging devices
- Reported evidence
- Clearance summaries define intended use, and dose guidance publishes typical CT effective-dose ranges.
- Announced next step
- Frameworks for adaptive and learned components in cleared devices.
- Unresolved risk
- Clearance is not evidence of outcome benefit, and locked-model clearance sits awkwardly with continuously updated software.
Systems and status are reproduced from the research record below. A clearance is a statement about intended use and safety, not about outcome benefit, and naming a system here does not imply an endorsement or a procurement recommendation.
The access frontier is moving
Portability is not equivalence. A 2026 meta-analysis found moderate performance for portable low-field MRI in acute ischemic stroke and cautioned against using it alone to rule disease out.
The discovery chain
Imaging advances when a new signal, a better detector, and enough computation become clinically usable at the same time.
- 1895
X-rays
A new penetrating signal made internal anatomy visible without surgery.
- 1950s
Clinical ultrasound
Pulse-echo systems adapted sonar physics to living tissue.
- 1971
First clinical CT
Reconstruction separated overlapping anatomy into cross-sections.
- 1980s
Commercial MRI and PET
Magnetic resonance expanded soft-tissue contrast while PET mapped molecular activity.
- 1998-2001
PET/CT
Registration of molecular and anatomical images moved from prototype to commercial systems.
- 2021
Photon-counting CT
The first FDA-cleared system counted individual X-ray photons and their energy.
- 2020s
Portable MRI and AI reconstruction
Lower-field magnets and computation began moving advanced imaging toward the bedside.
More answer per unit of infrastructure
The durable trend is not that every flagship machine gets cheaper. It is that useful information migrates into smaller systems, shorter protocols, and wider clinical settings.
Detectors count more of the signal
Digital radiography removed film. Solid-state ultrasound and PET detectors improved sensitivity. Photon-counting CT extracts energy information from individual events.
Cost lever: less dose, fewer repeats, more information per acquisitionComputation replaces brute force
Iterative reconstruction, compressed sensing, motion correction, and learned denoising can recover useful images from faster or weaker acquisitions.
Cost lever: shorter slots and lower infrastructure demandHardware leaves the suite
Mobile radiography, handheld ultrasound, and portable low-field MRI move the scanner to emergency rooms, intensive care, rural clinics, and bedsides.
Cost lever: less patient transport and lighter sitingProtocols become task-specific
A focused ultrasound or rapid MRI protocol can answer one narrow question without reproducing a comprehensive radiology examination.
Cost lever: match evidence to the decisionNetworks pool scarce expertise
Cloud archives, teleradiology, remote quality control, and decision support separate image acquisition from specialist location.
Cost lever: higher utilization and wider interpretation accessManufacturing gains a second market
Refurbishment, modular platforms, and software upgrades extend equipment life, though cybersecurity and parts support can end it early.
Cost lever: spread embodied capital across more yearsThe invoice is a small part of the cost
A scanner has one price. An examination has a production cost that depends on the room, the service contract, the staff, the tracer, and above all on how often the machine is used.
The cost stack
Bars are qualitative, not shares. Their purpose is to show why a cheaper magnet or detector does not translate one-for-one into a cheaper examination. The model below makes the same argument quantitatively.
What does one examination cost to produce?
Production cost is not a charge, a reimbursement, or a patient bill. Change the assumptions and watch which line dominates.
Estimated production cost
- Capital recovery
- $17 · 15%
- Service and maintenance
- $10 · 9%
- Operator and interpretation
- $55 · 47%
- Contrast, tracer, disposables
- $35 · 30%
10-year equipment life; 8% real cost of capital; annual service 9% of installed cost; 50 operating weeks. Excludes construction financing, referral and scheduling overhead, repeat scans, and the cost of a missed or false-positive finding.
Calculation & assumptions
Cost per exam = installed cost × (capital recovery factor + annual service rate) ÷ annual examinations + per-exam labour + per-exam consumables. Installed cost = equipment price × (1 + siting percentage).
Capital recovery uses the scenario's real discount rate and equipment life. Utilisation is expressed directly as examinations per week, which is where low-volume sites lose most of their economics: halving throughput roughly doubles the capital and service share per exam.
The remaining bottlenecks are system bottlenecks
Imaging can fail even when the scanner works perfectly. Physics, workflow, institutions, and evidence all set the boundary.
The signal budget
Spatial resolution, time, dose, penetration, and noise are coupled. Better algorithms stretch the budget; they do not repeal counting statistics or tissue physics.
The room around the scanner
Power, shielding, cooling, coils, injectors, service, safety zones, and construction can rival the machine in determining access.
People and workflow
A device needs trained operators, protocol selection, quality assurance, reporting, follow-up, and a referral system. Hardware alone does not produce care.
Evidence and generalization
A reconstruction model may fail on an unfamiliar scanner, body type, implant, disease, or protocol. Prospective clinical validation is slower than software iteration.
The last-mile price
Purchase prices can fall while patient prices remain high because utilization, reimbursement, staffing, financing, and local market power set the delivered cost.
Overuse and incidental findings
More accessible imaging can create low-value scans and cascades of follow-up. The frontier is the right scan at the right time, not simply more scans.
An optimistic view, with conditions
Imaging becomes a distributed measurement layer
The strongest plausible future is not one universal scanner. It is a ladder: ubiquitous low-cost tools identify who needs escalation, fast local systems answer common questions, and high-end centers resolve the difficult remainder.
Focused exams spread
Handheld ultrasound, rapid protocols, photon-counting CT, and portable MRI expand where imaging can happen. Workflow and training determine the real gain.
Acquisition gets adaptive
Systems stop when sufficient evidence is collected, choose views from live uncertainty, and route equivocal cases upward instead of pretending every image is definitive.
Price follows the whole pathway
Payment rewards avoided delays and better outcomes, not scan volume alone. Shared infrastructure and remote expertise turn falling hardware cost into falling delivered cost.
View the analyst probability ranges
| Milestone | Date | Analyst probability |
|---|---|---|
| Photon-counting CT available at most large referral centres | 2032 | 50-70% |
| Portable low-field MRI routine in stroke and intensive-care pathways | 2032 | 30-50% |
| Learned reconstruction in the default protocol on most new scanners | 2030 | 60-80% |
| A large trial shows portable imaging improves outcomes, not only access | 2033 | 20-35% |
| Delivered price of a common cross-sectional exam falls materially in a high-cost market | 2035 | 15-30% |
| Autonomous reporting cleared for a narrow, defined screening task | 2032 | 25-45% |
Editorial judgements conditional on the record above. They are not vendor guidance, published forecasts, or statistical confidence intervals.
There is more than one finish line
- Technically readableThe system produces a recognizable image.
- Diagnostically adequateThe evidence answers one defined clinical question.
- Workflow compatibleAcquisition, interpretation, and reporting fit real care.
- Economically accessibleTotal delivered cost supports broad and equitable use.
- Outcome improvingEarlier or better decisions materially improve health.
Sources, method, and boundaries
The historical figure is an editorial reconstruction, not a continuous price series. It combines documented purchase-price anchors with rounded CPI conversion and approximate entry-market endpoints. It does not compare equal capability and should not be used for procurement or patient billing. Clinical performance statements describe populations and systems in cited research, not advice for an individual patient.
- Measured
- A reported physical or clinical observation.
- Purchase price
- Equipment cost before some or all construction, service, staffing, and consumables.
- Entry boundary
- A lower available tier that may have narrower indications than a premium system.
- Analytical reconstruction
- A connected estimate from sparse, non-like-for-like benchmarks.